DOCSLIB.ORG

Pharmaceutical Benefits Scheme Codes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmaceutical Benefits Scheme Codes Supplementary material BMJ Open PHARMACEUTICAL BENEFITS SCHEME CODES AMT MPP = Australian Medical Terminology Medicinal Product Pack, ATC = Anatomical Therapeutic Chemical, PBS = Pharmaceutical Benefits Scheme codes Summary of drug categories and ATC codes used to identify PBS codes Function Examples ATC codes Antiplatelet Aspirin, clopidogrel, prasugrel, B01AC04, B01AC06, B01AC22, ticagrelor B01AC24, B01AC30 Lipid modification Statins, fibrates C09~, C10AA~, C10AB~, C10AC~, C10AD~, C10AX~, C10AX09, C10AX13, C10BA~, C10BX~ Symptom relief ß-blockers, nitrates, calcium channel C01DA~, C01DX16, C01EB17, C07AA~ blockers C07AB~, C07AG~, C08CA~, C08CX~, C08DA~, C08DB~, C08EA~, C08EX~, C08GA~ Full list of PBS codes used in this research PBS ATC code Drug category Drug name AMT MPP name code 8358X B01AC04 Antiplatelet clopidogrel clopidogrel 75 mg tablet, 28 5436D B01AC04 Antiplatelet clopidogrel clopidogrel 75 mg tablet, 28 9317J B01AC04 Antiplatelet clopidogrel clopidogrel 75 mg tablet, 28 4179Y B01AC04 Antiplatelet clopidogrel clopidogrel 75 mg tablet, 28 9354H B01AC04 Antiplatelet clopidogrel clopidogrel 75 mg tablet, 28 2275R B01AC04 Antiplatelet clopidogrel clopidogrel 75 mg tablet, 28 8202Q B01AC06 Antiplatelet aspirin aspirin 100 mg tablet, 112 4078P B01AC06 Antiplatelet aspirin aspirin 100 mg capsule: enteric, 84 4076M B01AC06 Antiplatelet aspirin aspirin 100 mg tablet, 90 4077N B01AC06 Antiplatelet aspirin aspirin 100 mg tablet: enteric, 84 1010E B01AC06 Antiplatelet aspirin aspirin 300 mg tablet: effervescent, 96 9495R B01AC22 Antiplatelet prasugrel prasugrel 5 mg tablet, 28 9496T B01AC22 Antiplatelet prasugrel prasugrel 10 mg tablet, 28 1418P B01AC24 Antiplatelet Ticagrelor Ticagrelor Tablet 90 mg, 56 8382E B01AC30 Antiplatelet dipyridamole + aspirin dipyridamole 200 mg + aspirin 25 mg capsule: modified release, 60 capsules 9296G B01AC30 Antiplatelet clopidogrel + aspirin clopidogrel 75 mg + aspirin 100 mg tablet, 30 1516T C01DA02 Nitrate glyceryl trinitrate glyceryl trinitrate 10 mg/24 hours patch, 30 1515R C01DA02 Nitrate glyceryl trinitrate glyceryl trinitrate 5 mg/24 hours patch, 30 8027L C01DA02 Nitrate glyceryl trinitrate glyceryl trinitrate 5 mg/24 hours patch, 30 8011P C01DA02 Nitrate glyceryl trinitrate glyceryl trinitrate 10 mg/24 hours patch, 30 2588F C01DA08 Nitrate isosorbide dinitrate isosorbide dinitrate 5 mg tablet: sublingual, 100 McCreanor V, et al. BMJ Open 2019; 9:e029360. doi: 10.1136/bmjopen-2019-029360 Supplementary material BMJ Open PBS ATC code Drug category Drug name AMT MPP name code 5108W C01DA02 Nitrate glyceryl trinitrate glyceryl trinitrate 600 microgram tablet: sublingual, 100 tablets 1558B C01DA14 Nitrate isosorbide isosorbide mononitrate 60 mg tablet: modified mononitrate release, 30 tablets 8028M C01DA02 Nitrate glyceryl trinitrate glyceryl trinitrate 10 mg/24 hours patch, 30 3475X C01DA02 Nitrate glyceryl trinitrate glyceryl trinitrate 400 microgram/actuation spray, 200 actuations 1459T C01DA02 Nitrate glyceryl trinitrate glyceryl trinitrate 600 microgram tablet: sublingual, 100 tablets 8026K C01DA02 Nitrate glyceryl trinitrate glyceryl trinitrate 15 mg/24 hours patch, 30 8171C C01DA02 Nitrate glyceryl trinitrate glyceryl trinitrate 400 microgram/actuation spray, 200 actuations 8273K C01DA14 Nitrate isosorbide isosorbide mononitrate 120 mg tablet: modified mononitrate release, 30 tablets 8119H C01DA02 Nitrate glyceryl trinitrate glyceryl trinitrate 15 mg/24 hours patch, 30 8010N C01DA02 Nitrate glyceryl trinitrate glyceryl trinitrate 5 mg/24 hours patch, 30 8229D C01DX16 Vasodilator nicorandil nicorandil 20 mg tablet, 60 8228C C01DX16 Vasodilator nicorandil nicorandil 10 mg tablet, 60 2960T C01EB17 Symptom relief - ivabradine ivabradine 7.5 mg tablet, 56 other 10012Y C01EB17 Symptom relief - ivabradine ivabradine 5 mg tablet, 56 other 2942W C07AA02 Beta blocker oxprenolol oxprenolol hydrochloride 20 mg tablet, 100 2566C C07AA05 Beta blocker propranolol propranolol hydrochloride 40 mg tablet, 100 2899N C07AA05 Beta blocker propranolol propranolol hydrochloride 160 mg tablet, 50 3062E C07AA03 Beta blocker pindolol pindolol 5 mg tablet, 100 2565B C07AA05 Beta blocker propranolol propranolol hydrochloride 10 mg tablet, 100 2961W C07AA02 Beta blocker oxprenolol oxprenolol hydrochloride 40 mg tablet, 100 3065H C07AA03 Beta blocker pindolol pindolol 15 mg tablet, 50 2243C C07AB03 Beta blocker atenolol atenolol 50 mg/10 mL oral liquid, 300 mL 8733P C07AB02 Beta blocker metoprolol succinate metoprolol succinate Tablet 47.5 mg (controlled release), 30 1325R C07AB02 Beta blocker metoprolol tartrate metoprolol tartrate Tablet 100 mg, 60 8735R C07AB02 Beta blocker metoprolol succinate metoprolol succinate Tablet 190 mg (controlled release), 30 8732N C07AB02 Beta blocker metoprolol succinate metoprolol succinate Tablet 23.75 mg (controlled release), 15 8604W C07AB07 Beta blocker bisoprolol bisoprolol fumarate 2.5 mg tablet, 28 9311C C07AB12 Beta blocker nebivolol nebivolol 5 mg tablet, 28 8605X C07AB07 Beta blocker bisoprolol bisoprolol fumarate 5 mg tablet, 28 9316H C07AB12 Beta blocker nebivolol nebivolol 1.25 mg tablet, 28 8734Q C07AB02 Beta blocker metoprolol succinate metoprolol succinate Tablet 95 mg (controlled release), 30 1081X C07AB03 Beta blocker atenolol atenolol 50 mg tablet, 30 9312D C07AB12 Beta blocker nebivolol nebivolol 10 mg tablet, 28 8606Y C07AB07 Beta blocker bisoprolol bisoprolol fumarate 10 mg tablet, 28 1324Q C07AB02 Beta blocker metoprolol tartrate metoprolol tartrate Tablet 50 mg, 100 1567L C07AG01 Beta blocker labetalol labetalol hydrochloride 200 mg tablet, 100 McCreanor V, et al. BMJ Open 2019; 9:e029360. doi: 10.1136/bmjopen-2019-029360 Supplementary material BMJ Open PBS ATC code Drug category Drug name AMT MPP name code 8256M C07AG02 Beta blocker carvedilol carvedilol 6.25 mg tablet, 60 8258P C07AG02 Beta blocker carvedilol carvedilol 25 mg tablet, 60 8257N C07AG02 Beta blocker carvedilol carvedilol 12.5 mg tablet, 60 1566K C07AG01 Beta blocker labetalol labetalol hydrochloride 100 mg tablet, 100 8255L C07AG02 Beta blocker carvedilol carvedilol 3.125 mg tablet, 30 8679T C08CA13 Calcium channel lercanidipine lercanidipine hydrochloride 20 mg tablet, 28 blocker 8534E C08CA13 Calcium channel lercanidipine lercanidipine hydrochloride 10 mg tablet, 28 blocker 1695F C08CA05 Calcium channel nifedipine nifedipine 20 mg tablet, 60 blocker 2367N C08CA02 Calcium channel felodipine felodipine 10 mg tablet: modified release, 30 blocker tablets 1907J C08CA05 Calcium channel nifedipine nifedipine 60 mg tablet: modified release, 30 blocker tablets 2752W C08CA01 Calcium channel amlodipine amlodipine 10 mg tablet, 30 blocker 2751T C08CA01 Calcium channel amlodipine amlodipine 5 mg tablet, 30 blocker 1906H C08CA05 Calcium channel nifedipine nifedipine 30 mg tablet: modified release, 30 blocker tablets 2361G C08CA02 Calcium channel felodipine felodipine 2.5 mg tablet: modified release, 30 blocker tablets 8610E C08CA05 Calcium channel nifedipine nifedipine 20 mg tablet: modified release, 30 blocker tablets 1694E C08CA05 Calcium channel nifedipine nifedipine 10 mg tablet, 60 blocker 2366M C08CA02 Calcium channel felodipine felodipine 5 mg tablet: modified release, 30 tablets blocker 1250T C08DA01 Calcium channel verapamil verapamil hydrochloride 80 mg tablet, 100 blocker 2207E C08DA01 Calcium channel verapamil verapamil hydrochloride 240 mg capsule: modified blocker release, 30 capsules 2206D C08DA01 Calcium channel verapamil verapamil hydrochloride 160 mg capsule: modified blocker release, 30 capsules 1248Q C08DA01 Calcium channel verapamil verapamil hydrochloride 40 mg tablet, 100 blocker 2208F C08DA01 Calcium channel verapamil verapamil hydrochloride 180 mg tablet: modified blocker release, 30 tablets 1241H C08DA01 Calcium channel verapamil verapamil hydrochloride 240 mg tablet: modified blocker release, 30 tablets 1312C C08DB01 Calcium channel diltiazem diltiazem hydrochloride 180 mg capsule: modified blocker release, 30 capsules 1335G C08DB01 Calcium channel diltiazem diltiazem hydrochloride 60 mg tablet, 90 blocker 1313D C08DB01 Calcium channel diltiazem diltiazem hydrochloride 240 mg capsule: modified blocker release, 30 capsules 8480H C08DB01 Calcium channel diltiazem diltiazem hydrochloride 360 mg capsule: modified blocker release, 30 capsules 2147B C09CA08 Renin- olmesartan medoxomil olmesartan medoxomil 20 mg tablet, 30 angiotensin system agent McCreanor V, et al. BMJ Open 2019; 9:e029360. doi: 10.1136/bmjopen-2019-029360 Supplementary material BMJ Open PBS ATC code Drug category Drug name AMT MPP name code 1182F C09AA09 Renin- fosinopril fosinopril sodium 10 mg tablet, 30 angiotensin system agent 1183G C09AA09 Renin- fosinopril fosinopril sodium 20 mg tablet, 30 angiotensin system agent 2836G C09DX03 Renin- olmesartan + olmesartan medoxomil 40 mg + amlodipine 10 mg angiotensin amlodipine + + hydrochlorothiazide 12.5 mg tablet, 30 system agent hydrochlorothiazide 2136K C09DA04 Renin- irbesartan + irbesartan 300 mg + hydrochlorothiazide 25 mg angiotensin hydrochlorothiazide tablet, 30 system agent 8590D C09BA06 Renin- quinapril + quinapril 20 mg + hydrochlorothiazide 12.5 mg angiotensin hydrochlorothiazide tablet, 30 system agent 10005N C09DX03 Renin- olmesartan + olmesartan medoxomil 20 mg + amlodipine 5 mg + angiotensin amlodipine + hydrochlorothiazide 12.5 mg tablet, 30 system agent hydrochlorothiazide 9120B C09AA05 Renin- ramipril ramipril 1.25 mg capsule, 30 angiotensin system agent 3050M C09AA04 Renin- perindopril perindopril erbumine 2 mg tablet, 30 angiotensin system
Load more

Recommended publications
  • Key Features of Candesartan Cilexetil and a Comparison with Other Angiotensin II Receptor Antagonists
    Journal of Human Hypertension (1999) 13, (Suppl 1), S3–S10 1999 Stockton Press. All rights reserved 0950-9240/99 $12.00 Key features of candesartan cilexetil and a comparison with other angiotensin II receptor antagonists PS Sever Imperial College of Science, Technology & Medicine at St Mary’s Hospital, London, UK Current research on angiotensin II AT1-receptor antag- in patients with essential hypertension. Candesartan onists (AIIRAs) and selected studies presented at the cilexetil has a rapid onset of action (approximately 80% recent symposium held in Amsterdam, The Netherlands, of total blood pressure reduction within the first 2 on 6 June 1998, titled ‘Angiotensin II Receptor Antagon- weeks) and dose-dependent effects on blood pressure, ists are NOT all the Same’ are reviewed. AIIRAs offer a is comparable in efficacy to a number of classes of anti- number of potential advantages over alternative antihy- hypertensives, and is effective in combination therapy pertensive agents acting via the renin-angiotensin-aldo- (eg, with hydrochlorothiazide and amlodipine). This sterone system. They combine blood pressure-lowering favourable profile may be due in part to the highly selec- effects at least equivalent to those of angiotensin-con- tive, tight binding to and slow dissociation of candesar- verting enzyme (ACE) inhibitors, coupled with placebo- tan from the AT1 receptor. Preliminary studies suggest like tolerability. Candesartan cilexetil is a novel AIIRA that candesartan cilexetil also protects end organs that has demonstrated clinical
    [Show full text]
  • Effective Dose Range of Enalapril in Mild to Moderate Essential Hypertension
    Br. J. clin. Pharmac. (1985), 19, 605-611 Effective dose range of enalapril in mild to moderate essential hypertension R. BERGSTRAND', H. HERLITZ2, SAGA JOHANSSON', G. BERGLUND2, A. VEDIN', C. WILHELMSSON', H. J. GOMEZ3, V. J. CIRILLO3 & J. A. BOLOGNESE4 'Department of Medicine, Ostra Hospital and 2Department of Medicine I, Sahlgrenska Hospital, Goteborg, Sweden and Department of 3Cardiovascular Clinical Research and 4Clinical Biostatistics, Merck Sharp & Dohme Research Laboratories, Rahway, New Jersey, USA 1 The dose-response relationship of enalapril was evaluated in a double-blind, balanced, two-period, incomplete-block study in 91 patients with mild to moderate essential hyper- tension. 2 Patients were randomly assigned to two of six treatments: placebo, 2.5, 5, 10, 20 and 40 mg/day of enalapril maleate. There were two 3-week treatment periods, each preceded by a 4-week, single-blind placebo washout. 3 Each dose of enalapril produced significant decreases in standing and supine systolic and diastolic blood pressure after 2 and 3 weeks of treatment. There were no significant changes on placebo. 4 There was a significant linear dose response relationship for both mean blood pressure and mean change from baseline in blood pressure (P < 0.01 for systolic and mean arterial pressure, and P < 0.05 for diastolic pressure). 5 Enalapril was associated with an increasing dose-response relationship across the 2.5- 40 mg/day range. The 2.5 mg/dose is effective in some patients; however, doses ¢ 10 mg/ day may be necessary to achieve satisfactory blood pressure control. Keywords enalapril angiotensin converting enzyme inhibitor dose-response relationship Introduction In recent years much interest has been focused with renal impairment treated with high doses of on angiotensin converting enzyme (ACE) in- captopril.
    [Show full text]
  • A Comparison of the Tolerability of the Direct Renin Inhibitor Aliskiren and Lisinopril in Patients with Severe Hypertension
    Journal of Human Hypertension (2007) 21, 780–787 & 2007 Nature Publishing Group All rights reserved 0950-9240/07 $30.00 www.nature.com/jhh ORIGINAL ARTICLE A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension RH Strasser1, JG Puig2, C Farsang3, M Croket4,JLi5 and H van Ingen4 1Technical University Dresden, Heart Center, University Hospital, Dresden, Germany; 2Department of Internal Medicine, La Paz Hospital, Madrid, Spain; 31st Department of Internal Medicine, Semmelweis University, Budapest, Hungary; 4Novartis Pharma AG, Basel, Switzerland and 5Novartis Institutes for Biomedical Research, Cambridge, MA, USA Patients with severe hypertension (4180/110 mm Hg) LIS 3.4%). The most frequently reported AEs in both require large blood pressure (BP) reductions to reach groups were headache, nasopharyngitis and dizziness. recommended treatment goals (o140/90 mm Hg) and At end point, ALI showed similar mean reductions from usually require combination therapy to do so. This baseline to LIS in msDBP (ALI À18.5 mm Hg vs LIS 8-week, multicenter, randomized, double-blind, parallel- À20.1 mm Hg; mean treatment difference 1.7 mm Hg group study compared the tolerability and antihyperten- (95% confidence interval (CI) À1.0, 4.4)) and mean sitting sive efficacy of the novel direct renin inhibitor aliskiren systolic blood pressure (ALI À20.0 mm Hg vs LIS with the angiotensin converting enzyme inhibitor À22.3 mm Hg; mean treatment difference 2.8 mm Hg lisinopril in patients with severe hypertension (mean (95% CI À1.7, 7.4)). Responder rates (msDBPo90 mm Hg sitting diastolic blood pressure (msDBP)X105 mm Hg and/or reduction from baselineX10 mm Hg) were 81.5% and o120 mm Hg).
    [Show full text]
  • Perindopril | Memorial Sloan Kettering Cancer Center
    PATIENT & CAREGIVER EDUCATION Perindopril This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: US Aceon [DSC] Brand Names: Canada AG-Perindopril; APO-Perindopril; Auro-Perindopril; BIO-Perindopril; Coversyl; JAMP-Perindopril; M-Perindopril Erbumine; MAR-Perindopril; MINT- Perindopril; NRA-Perindopril; PMS-Perindopril; Priva-Perindopril Erbumine; RIVA-Perindopril; SANDOZ Perindopril Erbumine; TEVA-Perindopril Warning Do not take if you are pregnant. Use during pregnancy may cause birth defects or loss of the unborn baby. If you get pregnant or plan on getting pregnant while taking this drug, call your doctor right away. What is this drug used for? It is used to treat high blood pressure. It is used to lower the risk of heart attack and death from heart disease in certain people. It may be given to you for other reasons. Talk with the doctor. Perindopril 1/7 What do I need to tell my doctor BEFORE I take this drug? If you are allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had. If you have ever had a very bad or life-threatening reaction called angioedema. Signs may be swelling of the hands, face, lips, eyes, tongue, or throat; trouble breathing; trouble swallowing; unusual hoarseness. If you have kidney disease. If you are taking a drug that has aliskiren in it and you also have diabetes or kidney problems.
    [Show full text]
  • AVAPRO Rx Only (Irbesartan) Tablets
    NDA 20-757/S-038 Page 3 ® AVAPRO Rx only (irbesartan) Tablets USE IN PREGNANCY When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. When pregnancy is detected, AVAPRO should be discontinued as soon as possible. See WARNINGS: Fetal/Neonatal Morbidity and Mortality. DESCRIPTION ®* AVAPRO (irbesartan) is an angiotensin II receptor (AT1 subtype) antagonist. Irbesartan is a non-peptide compound, chemically described as a 2-butyl-3-[p-(o-1H-tetrazol-5- ylphenyl)benzyl]-1,3-diazaspiro[4.4]non-1-en-4-one. Its empirical formula is C25H28N6O, and the structural formula: Irbesartan is a white to off-white crystalline powder with a molecular weight of 428.5. It is a nonpolar compound with a partition coefficient (octanol/water) of 10.1 at pH of 7.4. Irbesartan is slightly soluble in alcohol and methylene chloride and practically insoluble in water. AVAPRO is available for oral administration in unscored tablets containing 75 mg, 150 mg, or 300 mg of irbesartan. Inactive ingredients include: lactose, microcrystalline cellulose, pregelatinized starch, croscarmellose sodium, poloxamer 188, silicon dioxide and magnesium stearate. CLINICAL PHARMACOLOGY Mechanism of Action Angiotensin II is a potent vasoconstrictor formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system (RAS) and also stimulates aldosterone synthesis and secretion by adrenal NDA 20-757/S-038 Page 4 cortex, cardiac contraction, renal resorption of sodium, activity of the sympathetic nervous system, and smooth muscle cell growth.
    [Show full text]
  • Download Leaflet View the Patient Leaflet in PDF Format
    Package leaflet: Information for the patient Fosinopril Sodium 10 mg Tablets Fosinopril Sodium 20 mg Tablets Fosinopril sodium Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Fosinopril is and what it is used for 2. What you need to know before you take Fosinopril 3. How to take Fosinopril 4. Possible side effects 5. How to store Fosinopril 6. Contents of the pack and other information. 1. What Fosinopril is and what is it used for Fosinopril belongs to the class of medicines called Angiotensin Converting Enzyme (ACE) inhibitors that act on the heart and blood vessels. You may have been given Fosinopril to: • lower your blood pressure if it is too high (a condition called hypertension) • help your heart pump blood around your body if you have a condition known as heart failure and are also being treated with diuretics (medicines which help to remove excess fluid from the body). 2. What you need to know before you take Fosinopril Do not take Fosinopril: • if you are allergic to fosinopril or any other ACE inhibitor, or any of the other ingredients of this medicine (listed in section 6).
    [Show full text]
  • Cough Induced by Enalapril but Not by Captopril
    Eur Respir J 1989, 2, 289-291 CASE REPORT Cough induced by enalapril but not by captopril H. Puolijoki*, M. Nieminen*, E. Moilanen**, L. Siitonen*, A. Lahdensuo*, P. Reinikainen*, H. Vapaatalo** Cough iruluced by enalapril but 1101 by capropril. H. Puolijoki, M Nieminen, •Tampere University Central Hospital. E. Moilanen, L. Siironen, A. Lahdensuo, P. Reinikainen, If. VapaaJalo. •• Dept of Biomedical Sciences, University of ABSTRACT: We report a 68 yr old woman with hypertension wbo Tampcre. Finland. developed a dry cough on enalaprll but not on captopril therapy. Pul­ monary function te!its, methacholine in halation challenges, total blood Correspondence: H. Puolijoki, Dept of Pulmonary Diseases, Turlcu University Central Hospital, SF- eoslnophiJ counts, and changes In plasma concentrations or prostaglandin 207 40 Preitila, Finland. E2 and tllromboxane 81 did not explain the difference in the adverse reaction between tbese two angiotensin converting enzyme inhibitors. Keywords: ACE inhibitors; captopril; cough; Eur Respir J., 1989, 2, 289- 291. enalapril. Received: March, 1988; accepted after revision August 9, 1988. Angiotensin converting enzyme (ACE) inhibiLors like Case History capropril and ena1april are usually well tolerated. How­ ever, in some patientS they may cause cough as an A 68 yr old non-smoking woman with diabetes, adverse reaction [1]. We report a female patiem who hypertension and compensated heart failure, but with developed a cough on enalapril but not on captopril no respiratory disease or abnormalities on chest X-ray, therapy. We evaluated her lung function, bronchial re­ developed a dry cough but no dyspnoea or posrnasal activity to methacholine, LolaJ blood eosinophi l count as drip during Lreatmem with ena1april (Renitcc®, MSD, E 20 mg·day·1) for hypertension.
    [Show full text]
  • Ace Inhibitors (Angiotensin-Converting Enzyme)
    Medication Instructions Ace Inhibitors (Angiotensin-Converting Enzyme) Generic Brand Benazepril Lotensin Captopril Capoten Enalapril Vasotec Fosinopril Monopril Lisinopril Prinivil, Zestril Do not Moexipril Univasc Quinapril Accupril stop taking Ramipril Altace this medicine Trandolapril Mavik About this Medicine unless told ACE inhibitors are used to treat both high blood pressure (hypertension) and heart failure (HF). They block an enzyme that causes blood vessels to constrict. This to do so allows the blood vessels to relax and dilate. Untreated, high blood pressure can damage to your heart, kidneys and may lead to stroke or heart failure. In HF, using by your an ACE inhibitor can: • Protect your heart from further injury doctor. • Improve your health • Reduce your symptoms • Can prevent heart failure. Generic forms of ACE Inhibitors (benazepril, captopril, enalapril, fosinopril, and lisinopril) may be purchased at a lower price. There are no “generics” for Accupril, Altace Mavik, and of Univasc. Thus their prices are higher. Ask your doctor if one of the generic ACE Inhibitors would work for you. How to Take Use this drug as directed by your doctor. It is best to take these drugs, especially captopril, on an empty stomach one hour before or two hours after meals (unless otherwise instructed by your doctor). Side Effects Along with needed effects, a drug may cause some unwanted effects. Many people will not have any side effects. Most of these side effects are mild and short-lived. Check with your doctor if any of the following side effects occur: • Fever and chills • Hoarseness • Swelling of face, mouth, hands or feet or any trouble in swallowing or breathing • Dizziness or lightheadedness (often a problem with the first dose) Report these side effects if they persist: • Cough – dry or continuing • Loss of taste, diarrhea, nausea, headache or unusual fatigue • Fast or irregular heartbeat, dizziness, lightheadedness • Skin rash Special Guidelines • Sodium in the diet may cause you to retain fluid and increase your blood pressure.
    [Show full text]
  • Download Leaflet View the Patient Leaflet in PDF Format
    Package leaflet: Information for the user Candesartan cilexetil 2 mg tablets Candesartan cilexetil 4 mg tablets Candesartan cilexetil 8 mg tablets Candesartan cilexetil 16 mg tablets Candesartan cilexetil 32 mg tablets candesartan cilexetil Read all of this leaflet carefully If you are going to have an operation, before you start taking this tell your doctor or dentist that you are medicine because it contains taking Candesartan cilexetil. This is important information for you. because Candesartan cilexetil, when - Keep this leaflet. You may need combined with some anaesthetics, to read it again. may cause an excessive drop in - If you have any further questions, blood pressure. ask your doctor or pharmacist. - This medicine has been Children and adolescents prescribed for you only. Do not Candesartan Cilexetil has been pass it on to others. It may harm studied in children. For more them, even if their signs of illness information, talk to your doctor. are the same as yours. Candesartan Cilexetil must not be - If you get any side effects, talk to given to children under 1 year of your doctor or pharmacist. This age due to the potential risk to the includes any possible side effects developing kidneys. not listed in this leaflet. See Other medicines and Candesartan section 4. cilexetil What is in this leaflet Tell your doctor or pharmacist if you 1. What Candesartan cilexetil is and are taking, have recently taken or what it is used for might take any other medicines. 2. What you need to know before you take Candesartan cilexetil Candesartan cilexetil can affect the 3.
    [Show full text]
  • BENICAR HCT Tablets
    ® BENICAR HCT Tablets (OLMESARTAN MEDOXOMIL-HYDROCHLOROTHIAZIDE) WARNING: FETAL TOXICITY When pregnancy is detected, discontinue Benicar HCT as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. See Warnings: Fetal Toxicity DESCRIPTION BENICAR HCT® (olmesartan medoxomil-hydrochlorothiazide) is a combination of an angiotensin II receptor antagonist (AT1 subtype), olmesartan medoxomil, and a thiazide diuretic, hydrochlorothiazide (HCTZ). Olmesartan medoxomil, a prodrug, is hydrolyzed to olmesartan during absorption from the gastrointestinal tract. Olmesartan medoxomil is 2,3-dihydroxy-2-butenyl 4-(1-hydroxy-1-methylethyl)-2­ propyl-1-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]imidazole-5-carboxylate, cyclic 2,3­ carbonate. Its empirical formula is C29H30N6O6 and its structural formula is: Olmesartan medoxomil is a white to light yellowish-white powder or crystalline powder with a molecular weight of 558.6. It is practically insoluble in water and sparingly soluble in methanol. Hydrochlorothiazide is 6-chloro-3,4-dihydro-2H-1,2,4-benzo-thiadiazine-7-sulfonamide 1,1-dioxide. Its empirical formula is C7H8ClN3O4S2 and its structural formula is: 1 Reference ID: 3227549 Hydrochlorothiazide is a white, or practically white, crystalline powder with a molecular weight of 297.7. Hydrochlorothiazide is slightly soluble in water but freely soluble in sodium hydroxide solution. BENICAR HCT® is available for oral administration in tablets containing 20 mg or 40 mg of olmesartan medoxomil combined with 12.5 mg of hydrochlorothiazide, or 40 mg of olmesartan medoxomil combined with 25 mg of hydrochlorothiazide. Inactive ingredients include: hydroxypropylcellulose, hypromellose, lactose, low-substituted hydroxypropylcellulose, magnesium stearate, microcrystalline cellulose, red iron oxide, talc, titanium dioxide and yellow iron oxide.
    [Show full text]
  • Angiotensin-Converting Enzyme Inhibition but Not Angiotensin II Receptor Blockade Regulates Matrix Metalloproteinase Activity in Patients with Glomerulonephritis
    J Am Soc Nephrol 14: 2861–2872, 2003 Angiotensin-Converting Enzyme Inhibition but not Angiotensin II Receptor Blockade Regulates Matrix Metalloproteinase Activity in Patients with Glomerulonephritis NADE` GE LODS,* PAOLO FERRARI,* FELIX J. FREY,* ANDREAS KAPPELER,† CELINE BERTHIER,* BRUNO VOGT,* and HANS-PETER MARTI* *Division of Nephrology and Hypertension, Inselspital Bern, Bern, Switzerland; and †Institute of Pathology, University of Bern, Bern, Switzerland Abstract. Equivalent long-term effects on the kidney are attrib- periods of 4 wk each without therapy. Untreated patients with uted to angiotensin-converting enzyme inhibitors (ACEI) and glomerulonephritis displayed distinctively higher serum levels angiotensin II type 1 receptor blockers (ARB). Nevertheless, it of MMP-2 but much lower MMP-1/-8/-9 concentrations com- is unknown to which degree effects of these compounds on pared with healthy control subjects. Immunohistology of individual inflammatory mediators, including matrix metallo- MMP-2 and MMP-9 in kidney biopsy specimen was accord- proteinases (MMP), are comparable. On the basis of structural ingly. However, these patients excreted higher amounts of and functional differences, it was hypothesized that ACEI and MMP-2 and MMP-9 in urine than healthy control subjects, ARB differentially regulate MMP activity. In a randomized, possibly reflecting ongoing glomerular inflammation. In pa- prospective crossover trial, the effect of an ACEI (fosinopril; tients with glomerulonephritis, ACEI significantly reduced 20 mg/d) and of an ARB (irbesartan; 150 mg/d) on MMP overall MMP serum activity to 25%, whereas ARB did not activity was evaluated. Ten hypertensive patients with glomer- show any effect. Activities of MMP-1/-2/-8/-9 were also sig- ulonephritis and normal or mildly reduced creatinine clearance nificantly inhibited by fosinopril but not by irbesartan.
    [Show full text]
  • Effects of Olmesartan Vs Irbesartan on Metabolic Parameters and Visfatin in Hypertensive Obese Women
    European Review for Medical and Pharmacological Sciences 2010; 14: 759-763 Effects of olmesartan vs irbesartan on metabolic parameters and visfatin in hypertensive obese women D.A. DE LUIS, R. CONDE, M. GONZALEZ SAGRADO, R. ALLER, O. IZAOLA, J.L. PEREZ CASTRILLON, E. ROMERO, M.J. CASTRO Institute of Endocrinology and Nutrition, Medicine School and Unit of Investigation. Hospital Rio Hortega. RD-056/0013 RETICEF. University of Valladolid. Valladolid (Spain) Abstract. – Background: Angiotensin II reg- dence of this rising tide of obesity and associated ulates the production of adipokines. The objective pathologies has led, in the last years, to a dramat- was to study the effect of treatment with irbesartan versus olmesartan in obese hypertensive women. ic increase of researches on the role of adipose Subjects: A sample of 34 obese hypertensive tissue as an active participant in controlling the women was analyzed in a prospective way with a body’s physiology2. randomized trial. Patients were randomized to irbe- Visfatin was recently identified as a protein sartan (300 mg/day) or olmesartan (40 mg/day) for preferentially expressed in visceral adipose tis- 3 months. Weight, body mass index, blood pres- sue, compared with subcutaneous adipose tis- sure, basal glucose, insulin, total cholesterol, LDL- sue3. It can be found in skeletal muscle, liver, cholesterol, HDL-cholesterol, triglycerides, HOMA and visfatin were determined at basal time and af- bone marrow and lymphocytes, where it was ter 3 months of treatment. initially identified as pre-B-cell colony-enhanc- Results: Thirty four patients gave informed con- ing factor (PBEF). Fukuhara et al4 clearly sug- sent and were enrolled in the study.
    [Show full text]